Table 1 Conjugates components with cognate antigens and ASO targets

From: FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models

Conjugate

Antibody

Antibody antigen

Antibodyspecies reactivity

ASO

ASO target

DAR

ADC1

MAB01

TfR1

Mouse

ASO1

DMPK

1.49

FDC1

FAB02

TfR1

Human and cynomolgus monkey

ASO1

DMPK

1.20

FDC2

FAB01

TfR1

Mouse

ASO2

ACTA1

1.65

FDC3

FAB03

TfR1

Human and cynomolgus monkey

ASO1

DMPK

1.32

FDC4

FAB01

TfR1

Mouse

ASO1

DMPK

1.17

FDC5

FAB04

Picric Acid

N/A

ASO1

DMPK

1.30

FDC6

FAB05

Gp120

Human immunodeficiency virus

ASO3

DMPK

1.15

DYNE−101

FAB02

TfR1

Human and cynomolgus monkey

ASO3

DMPK

1.05

  1. FAB fragment antigen binding, MAB monoclonal antibody, ASO antisense oligonucleotide components, DAR drug antibody ratio, FDC antigen of each Fab–drug conjugate, ADC antibody–drug conjugate.
Back to article page